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We generated and compared Drosophila models of
RET fusions CCDC6-RET and NCOA4-RET. Both
RET fusions directed cells to migrate, delaminate,
and undergo EMT, and both resulted in lethality
when broadly expressed. In all phenotypes exam-
ined, NCOA4-RET was more severe than CCDC6-
RET, mirroring their effects on patients. A functional
screen against the Drosophila kinome and a library
of cancer drugs found that CCDC6-RET and
NCOA4-RET acted through different signaling net-
works and displayed distinct drug sensitivities.
Combining data from the kinome and drug screens
identified the WEE1 inhibitor AZD1775 plus the
multi-kinase inhibitor sorafenib as a synergistic
drug combination that is specific for NCOA4-RET.
Our work emphasizes the importance of identifying
and tailoring a patient’s treatment to their specific
RET fusion isoform and identifies a multi-targeted
therapy that may prove effective against tumors con-
taining the NCOA4-RET fusion.
INTRODUCTION
Rates of thyroid cancer have tripled in the last few decades,
making it the fastest growing cancer type (Brown et al., 2011).
80% of thyroid cancers are papillary thyroid carcinoma (PTC),
which arises from transformation of follicular cells in the thyroid.
PTC is a relatively indolent disease, with a 5-year survival rate of
98%. However, radioiodine-refractory disease has no effective
treatment, a 5-year survival rate of 50%, and results in the death
of 1,500 patients in the United States each year (Ricarte-
Filho et al., 2009). 30% of PTC cases are driven by RET fusion
proteins, generated as a result of a chromosomal translocation
that results in fusion of the RET receptor tyrosine kinase
to coiled-coil domains of various cytoplasmic proteins. RET
fusion proteins were first identified as oncogenes in PTC (Grieco
et al., 1990; Jhiang et al., 1992, 1996); more recently, they been
reported in other cancer types, including lung adenocarcinomas
(Kohno et al., 2012; Lipson et al., 2012; Takeuchi et al., 2012),
chronic myelomonocytic leukemia (Ballerini et al., 2012), and
colorectal cancer (Le Rolle et al., 2015). Two RET fusion iso-3052 Cell Reports 16, 3052–3061, September 13, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://forms, CCDC6-RET and NCOA4-RET, account for >90% of
PTC fusions (Santoro et al., 2006). Although both fusion proteins
lead to activation of Ret, the two isoforms are associated with
different PTC subtypes. CCDC6-RET is closely associated
with the classic variant, a more benign subtype; NCOA4-RET
is closely associated with the solid subtype, which is more
aggressive and malignant (Basolo et al., 2002; Rabes, 2001;
Thomas et al., 1999). The basis of this difference is poorly
understood.
Full-length RET phosphorylates downstream targets, resulting
in the activation of many signaling cascades, including the
Ras/ERK and phosphatidylinositol 3-kinase (PI3K)/AKT path-
ways, which in turn regulate cellular differentiation, proliferation,
and apoptosis (Wells and Santoro, 2009). Unlike their wild-type
counterpart, RET fusion proteins are not localized to the cell
membrane. Nevertheless, RET fusions signal through at least
some canonical RET signaling pathways (Castellone and San-
toro, 2008), though the full downstream effects of RET fusions
have not been fully explored (Knostman et al., 2007). Mitogen-
activated protein kinase (MAPK) inhibitors that show a strong
effect against the medullary thyroid carcinoma (MTC) human
cancer cell line TT had a modest effect against the CCDC6-
RET-harboring PTC human cancer cell line TPC1 (Gild et al.,
2013). These differences in drug response, in addition to the dif-
ferences in disease severity between fusion isoforms, suggest
that different RET isoforms may act at least in part through
distinct pathways, a testable hypothesis.
Previous work by our lab has validated Drosophila models
of oncogenic RET isoforms that are associated with MTC;
these models were used to explore function as well as identify
lead therapeutic hits for RET isoforms activated by point
mutation (Dar et al., 2012; Read et al., 2005; Vidal et al.,
2005). Here, we use Drosophila models to explore the role of
RET fusions in transformation. Drosophila models provide a
useful tool for examining oncogenes in situ: they provide
powerful genetic tools, and flies are sensitive to cancer-rele-
vant compounds (Edwards et al., 2011; Gladstone et al.,
2012; Rudrapatna et al., 2012; Slack et al., 2015; Willoughby
et al., 2013). Recently, multiple groups have studied the ability
of these RET fusions to transform cells in culture (Gild et al.,
2013; Knauf et al., 2003; Richardson et al., 2009; Wang
et al., 2003), providing important insights on their activity.
Whole-animal studies can provide further important informa-
tion on the interplay between tumor and non-tumor cells, as-
pects that are important both in the growth and metastasisuthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. CCDC6-RET and NCOA4-RET Directed Cell Migration and Whole-Animal Lethality in Drosophila
(A) Schematic of the full-length, wild-type RET gene and the two RET fusions (CCDC6-RET and NCOA4-RET).
(B) Histogram quantifying the percentage of larvae that matured to pupariation versus balancer controls (Ctrl: tub > w-/Tubby, CC6-R: tub > CCDC6-RET/
Tubby, NC4-R: tub > NCOA4-RET/Tubby). Animals expressing low levels of RET fusions under control of the tubulin-Gal4 driver died during larval stages.
GAL4 activity, and therefore expression levels, was controlled by temperature. tub>CCDC6-RET was expressed at a higher level (27C) yet led to only
42% larval lethality; tub>NCOA4-RET was expressed at lower levels (25C) and led to 100% larval lethality. Data are represented as mean ± SEM. **p% 0.01;
****p % 0.0001.
(C) An entire third-instar larval wing disc expressing GFP in the ptc expression domain. The perimeter of the wing is outlined to show the shape of the disc. Yellow
rectangle represents the region shown in (D)–(F0 0 ). Scale bar represents 315 mm.
(D–F0 0) Late third-instar larval wing discs expressing transgenes in the ptc expression domains as indicated; transformed cells were visualized with UAS-GFP.
(D0–F0) Localization with a phospho-RET antibody confirmed that human RET fusions are expressed and activated in Drosophila tissue. (D0 0–F0 0) Merged panels
highlight that only those cells expressing a RET fusion transgene activated RET. Scale bar in (F) represents 50 mm in (D)–(F0 0).
(G–I) z stack images of previously described wing discs showing migrating cells. Control animals (F) show no migration from endogenous ptc-GAL4 expression
domain, while ptc>CCDC6-RET (G) and ptc>NCOA4-RET (H) animals have one or more cells that have left the original space and migrated into wild-type
neighboring tissue; brackets show the distance cells have traveled from the posterior edge of the ptc domain, and white arrows indicate cells that have migrated.
Apical membrane is marked in blue with DE-cadherin staining, emphasizing that migrating cells have lost their polarity to invade along the basal membrane. Scale
bar in (G) represents 16.7 mm in (G)–(I).
(legend continued on next page)
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of tumors and in the response of tumors to therapy (Wagstaff
et al., 2013).
RET inhibitors have had moderate success in a small number
of patients with PTC or lung adenocarcinoma, having shown
considerable toxicity (Borrello et al., 2013; Horiike et al., 2016;
Xing et al., 2013). Thus, therapeutics for PTC remain a significant
unmet need. In this study, we examine signaling downstream of
the CCDC6-RET and NCOA4-RET fusions. Our data demon-
strate that these two RET fusion genes are functionally different,
both in the pathways that they utilize to promote transformation
and in their sensitivity to clinically relevant drugs.
RESULTS
RET Fusions Promoted Cell Migration, Delamination,
and EMT in Drosophila
To generate Drosophila models of CCDC6-RET and NCOA4-
RET, we created transgenic fly lines that express the human
fusion genes (Figure 1A) under the control of the UAS promoter.
Each construct was inserted into the same genomic site to
ensure that the UAS-CCDC6-RET and UAS-NCOA4-RET trans-
genes would be expressed at similar levels. Crossing in the 765-
Gal4 driver generated 765>CCDC6-RET and 765>NCOA4-RET,
leading to expression of the RET fusion constructs throughout
the developing wing disc. Staining with an antibody that recog-
nizes intracellular Ret, we confirmed that both RET fusions
were expressed at the same level (Figures 2G and S1); both hu-
man RET fusions were activated as assessed with an antibody
targeting the phosphorylated tyrosine epitope pTyr905, which
is required for downstream RET signaling (Figures 1D’-1F’, 2D,
and S1). Interestingly, 765>NCOA4-RET displayed a higher level
of activation than 765>CCDC6-RET (Figures 2D and S1), mirror-
ing the more severe disease presented by NCOA4-RET patients
(Basolo et al., 2002; Rabes, 2001; Thomas et al., 1999). Known
downstream effectors of RET signalingwere also activated in an-
imals expressing either RET fusion as shown by increased levels
of phosphorylated Erk and Jnk and increased levels of total
Rho1. However, one known effector, Rac1, was not upregulated
(Figures 2E, 2F, 2H, 2I, and S1).
The RET fusionswere next expressed in a central stripe of cells
in the developing wingmonolayer epithelium using the ptc-GAL4
driver; cells were visualized with a UAS-GFP reporter (Figures
1C–1I). Expression of either ptc>CCDC6-RET or ptc>NCOA4-
RET resulted in cells migrating away from the posterior border
of the ptc domain, where ptc expression is highest (Figures 1
and 2). Migrating cells detached from the apical membrane
and migrated through the basal layer of the epithelium (Figures
1G–1I). Flies expressing NCOA4-RET had significantly more
migrating cells than CCDC6-RET (Figures 1J and S2).
We have previously observed similar migration in other
Drosophila models (Rudrapatna et al., 2013; Vidal et al., 2010);
this migration was linked to an epithelial-to-mesenchymal transi-(J) Quantification of the severity of cell migration caused by each RET fusion expre
scored blind and binned into one of four categories (severe, moderate, weak, o
Again, despite differences in temperature, more ptc>CCDC6-RET (27C) was exp
displayed a significantly more severe phenotype. Data are represented as mean
See also Figure S2.
3054 Cell Reports 16, 3052–3061, September 13, 2016tion (EMT). The migrating ptc>CCDC6-RET and ptc>NCOA4-
RET cells stained positive for MMP1 and upregulated levels of
phosphorylated Src, two markers of EMT (Figure 2A–2C0 0). Cells
in ptc>CCDC6-RET and ptc>NCOA4-RET animals that were not
yet migrating also expressed higher levels of pSrc (Figure S3).
Ptc>NCOA4-RET cells expressed higher levels of EMT markers
(Figures 2B, 2C0 and S3), presumably reflecting the stronger acti-
vation of the RET fusion. Previous work in our lab has shown that
caspase activity is a component of a JNK-Rho1-actin signaling
axis that drives cell migration (Rudrapatna et al., 2013).We found
that migrating cells in ptc>CCDC6-RET and ptc>NCOA4-RET
animals stained positive for cleaved caspase-3, indicating these
cells are subject to a similar mechanism of migration (Figure S4).
The stronger phenotype observed in NCOA4-RET flies was re-
flected in other phenotypes. Broad expression of either RET
fusion via the tubulin-Gal4 promoter resulted in lethality: 42%
of tub>CCDC6-RET animals died in larval stages, while 100%
of tub>NCOA4-RET animals died as larvae (Figure 1B). This dif-
ference in signaling, cell migration, and lethality correlates with
the clinical observation that PTC patients with tumors harboring
NCOA4-RET typically present with a worse prognosis than
patients with CCDC6-RET tumors (Basolo et al., 2002; Rabes,
2001; Thomas et al., 1999). Overall, these data indicate that
Drosophila can provide a useful model for exploring specific
aspects of RET fusions in vivo.
CCDC6-RETandNCOA4-RETSignal throughShared and
Distinct Kinases
Kinases are a common regulatory feature of most signaling
networks. To explore the functional differences of CCDC6-
RET versus NCOA4-RET fusions in vivo, we conducted a
genetic modifier screen against the full Drosophila kinome.
Genetic modifier screens are a standard tool for identifying
functional effectors of a signaling protein (e.g., M€uller et al.,
2005; Simon, 1994; St Johnston, 2002; Ward et al., 2003).
One functional copy of each locus encoding a kinase was
removed, one by one, in the context of tub>CCDC6-RET or
tub>NCOA4-RET; we then assessed the ability of reduced
kinase activity to rescue animal lethality (Figure 3A). Despite
sharing an identical RET tyrosine kinase domain, CCDC6-
RET and NCOA4-RET displayed more functional differences
than similarities in the signaling networks that promoted
transformation (Figure 3). Mutations in six genes were identi-
fied as significant genetic modifiers of tub>CCDC6-RET and
eleven for tub>NCOA4-RET lethality; however, only two mod-
ifier loci were shared between the two RET fusions (Figures 3B
and S5). We identified regulators in a broad palate of signaling
pathways, including JNK, SRC, and STE20/Hippo (Figure 3B–
3D). These mostly non-overlapping sets of pathways indicate
that a significant proportion of CCDC6-RET and NCOA4-RET
signaling is distinct and that the two diseases may have signif-
icant qualitative differences.ssion under control of the ptc-GAL4 driver in larval wing discs. Wing discs were
r no migration). Example images for each category are provided in Figure S2.
ressed in the wing disc and less ptc>NCOA4-RET (25C), yet ptc>NCOA4-RET
± SEM. ****p% 0.0001.
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Figure 2. RET Fusions Directed EMT and
Upregulated Canonical Downstream Tar-
gets
(A–C) Third-instar larval wing discs expressing
transgeneswithin theptc-GAL4 expression domain.
(A0–C0 ) An antibody targeting MMP1 shows
that migrating cells expressed matrix metal-
loproteinases, enzymes upregulated during
mammalian EMT.
(A0 0–C0 0) An antibody against phosphorylated Src
shows that expression of either RET fusion led to
upregulation of activated Src, another marker of
EMT. Note that ptc>NCOA4-RET displayed more
cells expressing MMP1 and p-Src, correlating with
its more severe cell migration phenotype. Scale bar
in (C) represents 50 mm in (A)–(C0 0).
(D–I) Histograms quantifying western blots from
third-instar wing discs expressing either 765-Gal4
(control), 765>CCDC6-RET, or 765>NCOA4-RET.
Lysates were from 20 wings discs from each
genotype, and two biological replicates were
averaged. All animals were raised at 25C to
ensure similar levels of Gal4 expression; Fig-
ure S1 provides a representative blot con-
firming similar levels of RET fusion proteins in
(G). A phospho-RET antibody demonstrating
that NCOA4-RET has a higher level of kinase
activity as assessed by autophosphorylation
(D). Downstream signaling factors showed
elevated activation (phospho-Erk and phospho-
Jnk) or expression (Rho1). Data are represented
as mean ± SEM.
See also Figures S1, S3, and S4.CCDC6-RET and NCOA4-RET Were Sensitive to Shared
and Distinct Kinase Inhibitors
Previous work has demonstrated that RET fusions can be sensi-
tive to kinase inhibitors that target RET in cell culture (Carlo-
magno et al., 2002; Gild et al., 2013; Kim et al., 2006; Mologni
et al., 2013; Verbeek et al., 2011). The differences we observed
in signaling between CCDC6-RET and NCOA4-RET animals
indicate that they may be differentially sensitive to kinase inhib-
itors when assayed in a whole-animal context. We therefore
screened a set of 55 US Food and Drug Administration (FDA)-Cell Reportsapproved and experimental small-mole-
cule cancer therapies; larvae were fed
by mixing compounds directly into the
food. Compounds were fed at their
maximum tolerated dose, which ranged
from 1 mM to 200 mM. Maximum tolerated
dose was determined as the maximum
dose that had no detectable impact on
wild-type fly viability. Five compounds
rescued tub>CCDC6-RET, and five
rescued tub>NCOA4-RET lethality (Fig-
ures 4A, 4C, 4D, and S6; Table S1). Only
three compounds rescued both: the
multi-kinase FDA-approved inhibitors po-
natinib and regorafenib and the multi-ki-
nase inhibitor AD81; relative sensitivitiesto these drugs differed between the fusion models (Figures 4C,
4D, and S6; Table S1). Themajor targets of all seven compounds
that rescued either RET fusion are listed in Figure 4B.
Not all drug results matched our genetic screens; of note, all
the screened drugs have significant ‘‘off target’’ effects, so a
comparison is difficult. For example, gefitinib, developed as an
EGFR inhibitor, rescued tub>CCDC6-RET-mediated lethality,
yet heterozygosity of EGFR was not found to be a genetic
modifier in the kinome screen. Gefitinib’s efficacy may reflect
an off-target effect; alternatively, inhibiting EGFR activity more16, 3052–3061, September 13, 2016 3055
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Figure 3. RET Fusions Directed Similarities
and Differences in Signaling Networks
(A) Schematic of the kinome genetic modifier
screen.
(B) Venn diagram showing genetic modifier
hits from the kinome screen. In the background
of overexpression of either tub>CCDC6-RET or
tub>NCOA4-RET, kinases were assessed by (1)
heterozygosity via a hypomorphic or amorphic
allele or (2) RNAi-mediated knockdown. Loci were
considered hits that, when reduced, significantly
(p < 0.05) enhanced survival of the animal. Kinases
listed in Venn Diagram significantly suppressed
lethality induced by the specified RET fusion. Hu-
man orthologs of Drosophila kinases are listed in
superscript; legend indicates primary signaling
pathway for each hit. Note that most hits were
specific to one RET fusion isoform. Figure S5
provides the exact level of rescue.
(C) Histogram showing the genetic modifier hits
for tub>CCDC6-RET. Data are represented as
mean ± SEM. *p% 0.05; **p% 0.01.
(D) Histogram showing the genetic modifier hits for
tub>NCOA4-RET animals. Data are represented
as mean ± SEM. *p % 0.05; **p % 0.01; ****p %
0.0001.
See also Figure S5.than that achieved by a 50% gene reduction may be required to
significantly rescue lethality. Heterozygosity of pvr, encoding
the Drosophila ortholog to VEGFR, significantly rescued
tub>NCOA4-RET lethality, and indeed, several of the drugs
that rescued this model are known inhibitors of VEGFR (Figures
3B, 4A, and 4B). However, vandetanib has multiple kinase tar-
gets that include VEGFR, but it failed to rescue tub>NCOA4-
RET-mediated lethality. These discrepancies suggest that
complexity in a drug’s kinase profile can affect its activity against
specific oncogenes.
We investigated the effect that kinase inhibitors had on
migrating wing cells by feeding drugs to ptc>CCDC6-RET and
ptc>NCOA4-RET animals and visualizing transformed cells
with UAS-GFP. We tested two compounds, vandetanib and
AD81, because they displayed different abilities to rescue
whole-animal lethality induced by the RET fusions. Both com-
pounds rescued tub>CCDC6-RET flies to adulthood; only
AD81 was observed to rescue tub>NCOA4-RET flies. We
observed results similar to our viability assays; both vandetanib
and AD81 significantly reduced the number of cells leaving3056 Cell Reports 16, 3052–3061, September 13, 2016the ptc-GAL4 domain in ptc>CCDC6-
RET larvae, but only AD81 was observed
to rescue wing cell migration in
ptc>NCOA4-RET larvae (Figures 4E–4H
and S7).
A Rational Approach to Identifying
Synergistic Drug Combinations
Small-molecule kinase inhibitors are
commonly used to treat advanced tu-
mors. Recently, interest has risen in the
use of drug combinations to improveefficacy and to overcome resistance (Al-Lazikani et al., 2012;
Iadevaia et al., 2010; Keith et al., 2005; Shi et al., 2011; Yan
et al., 2010). However, identifying combinations in a rational
manner presents a challenge. As a first step in identifying optimal
drug combinations for RET fusion-based tumors in the context
of the whole animal, we combined our genetic modifiers iden-
tified in the kinome screen with hits from our drug screen.
More specifically, we removed a copy of each kinase that
rescued lethality while simultaneously feeding tub>CCDC6-
RET or tub>NCOA4-RET larvae each kinase inhibitor that
rescued lethality (Figure 5A). By testing each kinase functionally
linked to a RET fusion, our goal was to rationally identify activities
that pair synergistically with each active drug.
Our genetic screens proved successful in identifying
candidate kinase targets effective against NCOA4-RET trans-
formation. Most of our genetic modifiers of tub>NCOA4-RET
synergized with AD81, sorafenib, and regorafenib to enhance
survival to adulthood, since the combination of alleles and drugs
increased viability more than the sum of either single treat-
ment. For example, reducing one functional genomic copy of
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Figure 4. RET Fusions Were Sensitive to
Shared and Distinct Kinase Inhibitors
(A) Venn diagram of the seven hits from drug
screen that significantly increased the percent
of experimental animals that pupariated when
compared to control balancer flies. Figure S6
provides level of rescue of each hit. Table S1
shows the results for all 55 drugs tested and shows
exact p values of significant hits.
(B) Table indicating major targets of each kinase
inhibitor.
(C) Histogram showing the drug screen hits for
tub>CCDC6-RET. Data are represented as mean ±
SEM. *p% 0.05; **p% 0.01.
(D) Histogram showing the drug screen hits for
tub>NCOA4-RET. Data are represented as mean ±
SEM. **p% 0.01; ****p% 0.001.
(E–E0 0) Third-instar larval ptc>CCDC6-RET
wing discs. The ptc domain is visualized with
ptc>GFP. In contrast to DMSO controls, 100 mM
vandetanib and 100 mM AD81 blocked low-level
cell invasion. Scale bar in (E0 0) represents 50 mm
in (E)–(F0 0).
(F–F0 0) Third-instar larval ptc>NCOA4-RET wing
discs. In contrast to DMSO controls, AD81
blocked the extensive cell invasion phenotype,
while vandetanib had no impact on migrating
cells.
(G) Quantification of the severity of cell migration in
ptc>CCDC6-RET animals fed DMSO, vandetanib,
or AD81. Figure S7 shows the number of wing
discs that scored in each of the four categories and
provides p values for both ptc>CCDC6-RET and
ptc>NCOA4-RET.
(H) Quantification of the severity of cell migration in
ptc>NCOA4-RET animals fed DMSO, vandetanib,
or AD81.
See also Figures S6 and S7 and Table S1.the cell-cycle regulator wee (wee+/) led to near-100% rescue
when paired with AD81 or sorafenib and 68% rescue when
paired with regorafenib, while reducing wee to heterozygosity
when paired with DMSO control did not promote rescue of
viability in this context. Heterozygosity for the TEC and MYLK3
orthologs btk29A and sqa also significantly synergized with
these drugs (Figure 5B). Ponatinib and cabozantinib displayed
little to no synergy with any of the dominant modifier kinase
hits we tested (Figure 5B; Table S2).
In contrast, only reducing JNK activity (bsk+/) led to syner-
gistic rescue of tub>CCDC6-RET flies when combined with
any drug tested. Of note, heterozygosity for bsk also syner-
gized with many drugs that alone failed to detectably rescue
tub>CCDC6-RET flies (Figure 5C; Table S3), further empha-
sizing the sensitivity of CCDC6-RET fusion animals to reduc-
tion in JNK activity. These data are again consistent with
the view that CCDC6-RET and NCOA4-RET fusions act
through distinct networks and further indicate that rationally
selected drug combinations may prove useful as a therapeutic
approach.Synergistic Kinome plus Drug Combinations Inform
Drug Combinations
Of the genetic modifier hits that synergized with AD81, sorafenib,
or regorafenib in the context of NCOA4-RET overexpression, a
subset are targeted by validated kinase inhibitor compounds.
Ibrutinib is an FDA-approved inhibitor of TEC/BTK kinase used
for B cell tumors (Honigberg et al., 2010; Smith, 2015);
AZD1775 is aWEE1 inhibitor currently in clinical trials for multiple
solid tumors (e.g., Bridges et al., 2011; Do et al., 2015). HA-100 is
a pan-MYLK inhibitor that is not in clinical use; we used this com-
pound to determine whether chemical inhibition of MYLK3 can
have clinical relevance.
Mixing two-drug cocktails into their food, tub>NCOA4-RET
larvae were administered a cocktail of (1) AD81, sorafenib, or re-
gorafenib plus (2) ibrutinib, AZD1775, or HA-100. All three of the
latter drugs synergized with AD81, and AZD1775 displayed syn-
ergy with sorafenib (Figure 5D; Table S4). The strongest rescues
were observed with AD81 plus HA-100 or AD81 plus AZD1775.
The strongest rescue of NCOA4-RET with patient-available
drugs was sorafenib plus AZD1775.The levels of improvedCell Reports 16, 3052–3061, September 13, 2016 3057
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Figure 5. Rational Identification of Synergis-
tic Drug Cocktails
(A) Schematic of the genetic modifier and drug
screen.
(B) Histogram showing percent of tub>NCOA4-
RET larvae that matured to pupariation versus
balancer controls in the presence of drug plus
heterozygosity for the indicated locus. Heterozy-
gosity for most kinase loci synergized to rescue
lethality when combined with AD81, sorafenib, or
regorafenib. The most synergistic combinations
included heterozygosity for btk29A (TEC ortholog),
sqa (MYLK3 ortholog), or wee (WEE1 ortholog),
which increased the efficacy of AD81 on average
by 65.5%, sorafenib on average by 80%, and re-
gorafenib on average by 57.3%. Other drugs had
either no or minimal increased efficacy in the
context of any of the kinase alleles. Table S2 pro-
vides the level of rescue of each genetic and drug
combination.
(C) Histogram showing percent of tub>CCDC6-
RET animals that survived to adulthood in the
presence of drug plus heterozygosity for the indi-
cated locus. Baseline survival to adulthood (eclo-
sure) for tub>CCDC6-RET animals is 0%. The
ability of most drugs to improve viability was syn-
ergistically enhanced with the removal of one
functional copy of bsk (JNK ortholog). The best
combination for tub>CCDC6-RET animals is a
combination of bsk loss and AD81 treatment,
which rescued survival to 64%. Table S3 provides
the level of rescue of each genetic and drug com-
bination.
(D) Histogram showing drug combinations rescue
of lethality of tub>NCOA4-RET flies; ibrutinib
(TEC/BTK inhibitor), AZD1775 (WEE1), and HA-100
(MYLK) were chosen from data in (B). The optimal
combination for tub>NCOA4-RET animals was
HA-100 plus AD81. The optimal combination
available to patients was AZD1775 plus sorafenib.
Data are represented as mean ± SEM. Table S4
shows level of rescue for each drug combination.
See also Tables S2–S4.rescue rose to the level of synergy, suggesting that drug combi-
nations may provide improved outcome for patients with tumors
harboring the NCOA4-RET fusion.
DISCUSSION
As testing for the presence of chromosomal translocations has
become more common, RET fusion genes have been identified
in an increasing number of cancer types. Activating point muta-
tions in RET represent a clinically actionable target with several
FDA-approved inhibitors (Borrello et al., 2013; Elisei et al.,
2013; Kurzrock et al., 2011; Leboulleux et al., 2012). However,
current RET inhibitors may not prove as effective in treating pa-
tients with RET fusions. Here, we explore the properties of two
common RET fusions in the context of a whole-animal model.
Though both contain primarily coiled-coil domains, our studies
demonstrate that the N terminus partner of the common RET
fusions CCDC6-RET and NCOA4-RET differentially impact the
function and drug sensitivity of the fusion protein. Multiple differ-3058 Cell Reports 16, 3052–3061, September 13, 2016ences between the two fusions were observed in an in vivo
context. First, expressing NCOA4-RET led to more severe
phenotypes, including whole-body lethality and cell invasion,
mirroring the more aggressive phenotypes observed in patients
(Basolo et al., 2002; Rabes, 2001; Thomas et al., 1999). Second,
using an unbiased genetic screen of the Drosophila kinome,
we identified significant differences in the functional networks
used by each fusion to direct transformation-like phenotypes
(Figure 3).
The signaling differences between our two models led to a
difference in their response to therapeutics: tub>NCOA4-RET
and tub>CCDC6-RET animals displayed distinct responses to
drugs both as single agents and as two-drug cocktails (Figures
4 and 5). Regarding NCOA4-RET, the enhancement of sorafenib
by reducing wee activity was mirrored by the strong efficacy
of sorafenib plus AZD1775. This combination may prove useful
in refractory PTC or lung adenocarcinoma patients harboring
NCOA4-RET; additional mammalian in situ experiments will
be required to further assess its potential. We were unable to
identify a synergistic drug combination specific to CCDC6-RET,
consistent with our genetic results indicating the importance of
suppressing JNK activity in the presence of a broad spectrum
of kinase inhibitors (Figure 5C). As clinically relevant JNK inhibi-
tors are developed (Bennett et al., 2001; Davies and Tournier,
2012; Kaoud et al., 2011), they may prove useful for patients
with the less aggressive CCDC6-RET tumor isoforms. Also of
note, we focused on drugs and drug combinations that pro-
moted viability, perhaps a functional equivalent of cytostatic
activity. Future efforts to identify cytotoxic drugs would be initi-
ated by screening for drugs that promote lethality, including
cell lethality.
A key observation of our work is that the specific RET fusion is
important when considering tumor progression and appropriate
therapeutics. This will become increasingly important as addi-
tional tumors are identified as harboring particular RET fusions.
Whole-animal models such as Drosophila provide a useful tool
for understanding the mechanistic basis of how specific RET
fusions direct transformation. They can also provide useful
information on drugs and drug cocktails that attack the unique
networks activated by each RET isoform.
EXPERIMENTAL PROCEDURES
Generation of Drosophila Models of CCDC6-RET and NCOA4-RET
CCDC6-RET and NCOA4-RET cDNA was isolated from vectors pUGH10-3-
RET/PTC1 and pUGH10-3-RET/PTC3 (Knauf et al., 2003), which were pro-
vided by James Fagin (Memorial Sloan Kettering Cancer Center). Both cDNAs
were amplified from the pUGH10-3 vectors with primers that introduced Not1
sites on the 50 end and Xba1 sites on the 30 end and a Drosophila Kozac
sequence (CACC) to ensure efficient initiation of translation once inserted
into the Drosophila genome:
F-CCDC6: 50-GATCGCGGCCGCCACCATGGCGGACAGCGCCAGCG-30,
F-NCOA4: 50-GATCGCGGCCGCACCATGAATACCTTCCAAGACCA-30,
and
R-RET: 50-GATCTCTAGACTAGAATCTAGTAATGCATGGGAAATTCTA
CC-30.
pUAST-attB vector was cut with Not1 and Xba1 enzymes to clone in
CCDC6-RET or NCOA4-RET DNA.
Sequenced pUAST-attB-CCDC6-RET and pUAST-attB-NCOA4-RET vec-
tors were sent to BestGene to be injected in Drosophila embryos, targeting
both the attP2 and attP40 sites. Stable fly lines with single vector inserts
were kept as balanced stocks over (1) the CyO balancer for attP40 insertions
or (2) the TM6B balancer for attP2 insertions.
Immunohistochemistry
Wing discs from third-instar larvae were dissected on ice, fixed in 4% parafor-
maldehyde in PBS, washed in PBS containing 0.1% Triton X-100, and incu-
batedwith primary antibodies in PAXDG (PBS containing 1%BSA, 0.3%Triton
X-100, 0.3% deoxycholate, and 5% goat serum), followed by washing and
incubation with secondary antibodies in PAXDG. Tissues were mounted in
Vectashield mounting media (Vector Laboratories). Antibodies used were
directed against phosphorylated RET Tyr905 (Cell Signaling Technology
#3221), DE-cadherin (Developmental Studies Hybridoma Bank #DCAD2),
MMP1 (Developmental Studies Hybridoma Bank #3B8D12), and phosphory-
lated SRC (Invitrogen #44660G). Alexa Fluor secondary antibodies were
used. Confocal imaging used a Leica DM5500 Qmicroscope, and image anal-
ysis was performed using Adobe Photoshop.
Western Blots
20 wing discs from third-instar larvae expressing either CCDC6-RET or
NCOA4-RET under control of the 765-Gal4 driver and raised at the same tem-perature of 25C were dissected and dissolved in lysis buffer (50 mM Tris,
150 mM NaCl, 1% Triton X-100, and 1 mM EDTA) supplemented with prote-
ase-inhibitor cocktail and phosphatase-inhibitor cocktail (Sigma). Total pro-
tein was quantified using Bio-Rad protein assay. Samples were boiled,
resolved on SDS-PAGE, and transferred by standard protocols. Antibodies
used were directed against phospho-RET Tyr905 (Cell Signal #3221),
DE-cadherin (Developmental Studies Hybridoma Bank #DCAD2), Total RET
(Cell Signal #3223), phospho-Erk (Sigma-Aldrich #M8159), phospho-JNK/
SAPK (Cell Signal #4668), Rho1 (Developmental Studies Hybridoma Bank
#p1D9), Rac1 (BD Biosciences Pharmingen #610651) and Syntaxin (Devel-
opmental Studies Hybridoma Bank #8B-3). ImageJ software was used for
quantification.
Cell Migration
Wing discs from third-instar larvae were dissected and fixed in 4% formalde-
hyde. Approximately 20 discs per genotype were mounted to a slide, and the
severity of migration was scored in a blinded format.
Kinome Screen
Flies overexpressing either CCDC6-RET (UAS-CCDC6-RET;tubulin-Gal4/
Gal80ts) or NCOA4-RET (UAS-NCOA4-RET;tubulin-Gal4/Gal80ts) were
crossed to loss-of-function alleles for each Drosophila kinase. Positive
hits were scored for ratio of wild-type pupae to balancer (Tubby) pupae.
Drug Studies
Drugs were dissolved in DMSO to their maximum tolerated dose as
described in Table S1. Drug was added to molten (50C)-enriched fly
food and then aliquoted into 12 3 75-mm, 5-ml test tubes (Sarstedt catalog
no. B00471). After allowing for solidification at room temperature, each tube
contained 1 ml fly food and drug at a final DMSO concentration of 0.1%.
Five female flies (tubulinGal4/TM6B) and five male flies (UAS-CCDC6-RET
or UAS-NCOA4-RET) (both inserted at the attP40 chromosomal site) were
pre-mated for 3 days and then allowed to lay 30–60 embryos. Drug vials
were kept at 25C (NCOA4-RET) or 27C (CCDC6-RET) and scored for ratio
of wild-type pupae to balanced (Tubby) pupae. Drug studies were conduct-
ed in smaller vials as described above due to cost of the compounds.
These smaller vials induce more stress on the animal, which raises the level
of lethality slightly. Therefore, several of the hits from the kinome screens
did not show a rescue on their own when combined with DMSO in these
small vials, as they were originally identified with animals being raised in
their larger vials.
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